RAS activation drives critical downstream effectors (including PI3K, BRAF/CRAF and RAL) that not only potentiate tumour cell proliferation, and survival but also induce resistance to a wide range of therapeutics1, 2, 3, 4. The gene discussed is RAF1; the disease is neoplasm.